Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer On Boosters, Kids And Prospects For A Long-Term COVID-19 Business

Executive Summary

The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.

You may also be interested in...



Coronavirus Update: Pfizer/BioNTech Vaccine Shows Antibody Response In Young Kids

The companies announced data from their Phase II/III study in children aged 5-11 and intend to take them to regulators to expand Comirnaty's authorization; also, an expert panel advising India's drug regulator endorsed plans for a Phase III trial of a single-dose Russian vaccine, Sputnik Light, and vaccines from other Indian firms progress.

Coronavirus Update: Pfizer/BioNTech Send In Data For Booster Approval

Pfizer and BioNTech sent in Phase I data for a third dose of BNT162b2 to support future licensure, Gritstone bio will work with CEPI to develop its second-generation vaccine in South Africa and other areas, and Roche Genentech expects a shortage of the drug Actemra to last for several weeks amid a surge in cases.

Pfizer/BioNTech, Moderna Vaccines Take Baby Steps Into Booster Shots

Moderna may benefit from data indicating strong efficacy against the Delta strain, though an analyst pointed out that they come with some important caveats.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel